Correlation Between CeriBell, and MaxCyte
Can any of the company-specific risk be diversified away by investing in both CeriBell, and MaxCyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CeriBell, and MaxCyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between CeriBell, and MaxCyte, you can compare the effects of market volatilities on CeriBell, and MaxCyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CeriBell, with a short position of MaxCyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of CeriBell, and MaxCyte.
Diversification Opportunities for CeriBell, and MaxCyte
Modest diversification
The 3 months correlation between CeriBell, and MaxCyte is 0.22. Overlapping area represents the amount of risk that can be diversified away by holding CeriBell, and MaxCyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on MaxCyte and CeriBell, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CeriBell, are associated (or correlated) with MaxCyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of MaxCyte has no effect on the direction of CeriBell, i.e., CeriBell, and MaxCyte go up and down completely randomly.
Pair Corralation between CeriBell, and MaxCyte
Given the investment horizon of 90 days CeriBell, is expected to generate 0.98 times more return on investment than MaxCyte. However, CeriBell, is 1.02 times less risky than MaxCyte. It trades about -0.11 of its potential returns per unit of risk. MaxCyte is currently generating about -0.16 per unit of risk. If you would invest 2,586 in CeriBell, on December 30, 2024 and sell it today you would lose (640.00) from holding CeriBell, or give up 24.75% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
CeriBell, vs. MaxCyte
Performance |
Timeline |
CeriBell, |
MaxCyte |
CeriBell, and MaxCyte Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with CeriBell, and MaxCyte
The main advantage of trading using opposite CeriBell, and MaxCyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CeriBell, position performs unexpectedly, MaxCyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MaxCyte will offset losses from the drop in MaxCyte's long position.CeriBell, vs. BBB Foods | CeriBell, vs. Delta Air Lines | CeriBell, vs. Marfrig Global Foods | CeriBell, vs. Romana Food Brands |
MaxCyte vs. Sight Sciences | MaxCyte vs. CVRx Inc | MaxCyte vs. Neuropace | MaxCyte vs. Rapid Micro Biosystems |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Complementary Tools
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |